A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine if cognitive impairment induced by scopolamine is reversed using donepezil and/or AZD1446 as compared to placebo, as assessed by electroencephalogram (EEG) measures.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• BMI 18-30

• Non-smoker for at least 4 weeks

Exclusion Criteria:

• Any clinically relevant acute or chronic disease

• Hypersensitivity to scopolamine

• History of substance abuse